<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230409057864N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-08</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Oral Chloral Hydrate Syrup and Intranasal Midazolam for Calming Young Children During Echocardiography (Heart Ultrasound)</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Efficacy of Oral Chloral Hydrate and Intranasal Midazolam on Sedation in Children Aged 6 Months to 6 Years During Echocardiography: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/94606</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Eligible children will be individually allocated to the oral chloral hydrate group or the intranasal midazolam group (1:1) using block randomization with a block size of 4. Each of the six possible permutations of a 4-block (AABB=1, ABAB=2, ABBA=3, BBAA=4, BABA=5, BAAB=6) is assigned a number, and numbers between 1 and 6 are selected using a random number table to generate the allocation sequence. For allocation concealment, an independent researcher will write each group assignment on a card according to the random sequence and place it in an opaque, sealed container of identical shape and weight, numbered in the same order. After enrollment and parental consent, the next numbered container will be opened by the nurse responsible for drug administration, and the child will receive the drug written on the card. Thus, the group of the next participant cannot be known in advance, Blinding description: The study drugs will be prepared by an independent researcher who has no other role in the study. The drug will be given by a nurse who is not involved in sedation monitoring, outcome assessment or data analysis. The pediatric anesthesiologist who monitors the children during sedation (care provider), the investigator who performs echocardiography, and the data collector who records the outcomes (outcome assessor) will be unaware of the group allocation, because the drug will be given before the child enters the echocardiography room. The data analyst will receive the data with coded group labels and will not know which code belongs to which drug until the analysis is complete. Because the two drugs are given by different routes (oral and intranasal), the parents and the nurse who gives the drug cannot be blinded.</study_design>
      <phase>3</phase>
      <hc_freetext>Procedural sedation in children aged 6 months to 6 years undergoing transthoracic echocardiography.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Children in this group (n=50) will receive intranasal midazolam at a dose of 0.2 mg/kg. Midazolam injection vials (5 mg/mL) manufactured by Caspian Tamin Pharmaceutical Company (Iran) will be used. The calculated dose will be drawn from the vial, diluted 1:1 with 0.9% normal saline to a final volume of 0.5 mL, and administered slowly with a needle-free 1-mL syringe or sterile dropper, 0.25 mL into each nostril, with the child in the supine position. If adequate sedation (Modified Ramsay Sedation Score of 3 or higher) is not achieved within 10 minutes, an additional dose of intranasal midazolam 0.1 mg/kg will be given. Intervention 2: Control group: Children in this group (n=50) will receive oral chloral hydrate syrup (250 mg/5 mL or 500 mg/5 mL) manufactured by Caspian Tamin Pharmaceutical Company (Iran) at a dose of 50 mg/kg (maximum 2 g). The calculated dose will be mixed 1:1 with sour cherry juice or fruit syrup and given orally by the parents or a nurse. If adequate sedation (Modified Ramsay Sedation Score of 3 or higher) is not achieved within 10 minutes, an additional dose of intranasal midazolam 0.1 mg/kg will be given.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Participants are children, and the ethics approval and the informed consent signed by their parents only permit the study researchers to access the data. To protect participant confidentiality, individual participant data will not be shared, and only aggregate results will be published.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Ahmadipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Afzalipour Hospital, Kerman University of Medical Sciences, Imam Khomeini Highway, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3132 8000</telephone>
        <email>hsharifi@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Ahmadipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Afzalipour Hospital, Kerman University of Medical Sciences, Imam Khomeini Highway, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3132 8000</telephone>
        <email>hsharifi@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children aged 6 months to 6 years
Referred for transthoracic echocardiography requiring sedation
ASA physical status class I or II
Written informed consent obtained from parents or legal guardians</inclusion_criteria>
      <agemin>6 months</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Refusal of parents or legal guardians to participate
Nasal structural abnormality
Anticipated airway problem
Known allergy to midazolam or chloral hydrate
Organ dysfunction
Cardiac dysrhythmia
Intellectual disability</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z01.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other specified special examinations</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Children in this group (n=50) will receive intranasal midazolam at a dose of 0.2 mg/kg. Midazolam injection vials (5 mg/mL) manufactured by Caspian Tamin Pharmaceutical Company (Iran) will be used. The calculated dose will be drawn from the vial, diluted 1:1 with 0.9% normal saline to a final volume of 0.5 mL, and administered slowly with a needle-free 1-mL syringe or sterile dropper, 0.25 mL into each nostril, with the child in the supine position. If adequate sedation (Modified Ramsay Sedation Score of 3 or higher) is not achieved within 10 minutes, an additional dose of intranasal midazolam 0.1 mg/kg will be given.</i_keyword>
      <i_keyword>Control group: Children in this group (n=50) will receive oral chloral hydrate syrup (250 mg/5 mL or 500 mg/5 mL) manufactured by Caspian Tamin Pharmaceutical Company (Iran) at a dose of 50 mg/kg (maximum 2 g). The calculated dose will be mixed 1:1 with sour cherry juice or fruit syrup and given orally by the parents or a nurse. If adequate sedation (Modified Ramsay Sedation Score of 3 or higher) is not achieved within 10 minutes, an additional dose of intranasal midazolam 0.1 mg/kg will be given.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation duration. Timepoint: From achieving a Modified Ramsay Sedation Score of 3 or higher until eye opening. Method of measurement: Modified Ramsay Sedation Scale and recording of time (in minutes) using a stopwatch.</prim_outcome>
      <prim_outcome>Sedation onset time. Timepoint: From study drug administration until achieving a Modified Ramsay Sedation Score of 3 or higher. Method of measurement: Modified Ramsay Sedation Scale and recording of time (in minutes) using a stopwatch.</prim_outcome>
      <prim_outcome>Recovery time. Timepoint: From the end of echocardiography until spontaneous eye opening. Method of measurement: Observation and recording of time (in minutes) using a stopwatch.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Parental satisfaction. Timepoint: Before discharge. Method of measurement: 10-point satisfaction scale (1 = lowest to 10 = highest satisfaction).</sec_outcome>
      <sec_outcome>Heart rate. Timepoint: Before drug administration and at 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 minutes after drug administration. Method of measurement: Vital signs monitor (beats per minute).</sec_outcome>
      <sec_outcome>Oxygen saturation (SpO2). Timepoint: Before drug administration and at 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 minutes after drug administration. Method of measurement: Pulse oximeter (percent).</sec_outcome>
      <sec_outcome>Echocardiographer satisfaction with sedation quality and image quality. Timepoint: Immediately after completion of echocardiography. Method of measurement: 10-point satisfaction scale for sedation quality and 5-point scale for echocardiographic image quality.</sec_outcome>
      <sec_outcome>Adverse effects (SpO2 below 95%, bradycardia, nausea, vomiting and other complications). Timepoint: From drug administration until discharge. Method of measurement: Observation, vital signs monitoring and recording in the adverse effects checklist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-10-19</approval_date>
        <contact_name>Research Ethics Committee of Afzalipour Hospital, Kerman University of Medical Sciences</contact_name>
        <contact_address>Research Ethics Committee, Afzalipour Hospital, Kerman University of Medical Sciences, Imam Khomeini Highway, Kerman, Iran Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
